Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Medexus Pharmaceuticals Inc ( (TSE:MDP) ) is now available.
Medexus Pharmaceuticals reported continued progress in the U.S. commercialization of GRAFAPEX, with 56 transplant centers granting formulary inclusion and 64 centers placing orders as of March 31, 2026. Management said these adoption metrics align with expectations that GRAFAPEX will become accretive to operating cash flow starting in fiscal Q4 2026, supporting its goal of surpassing $100 million in annual net revenue within five years of launch.
The company also highlighted capital allocation moves, having repurchased 710,100 common shares under its normal course issuer bid for about $1.5 million and fully eliminating outstanding share purchase warrants, which it says reduces potential dilution and simplifies the capital structure. Medexus further plans to engage investors at upcoming healthcare conferences in Toronto and Los Angeles, underscoring its intent to raise its profile among institutional and retail stakeholders.
The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.
Spark’s Take on MDP Stock
According to Spark, TipRanks’ AI Analyst, MDP is a Neutral.
The score is primarily supported by improved financial quality—strong TTM free cash flow and a meaningfully deleveraged balance sheet—plus constructive price trend signals. It is held back by weak earnings-based valuation (negative P/E) and earnings-call risks around YoY revenue/earnings pressure and near-term launch investment drag despite improving GRAFAPEX adoption and guidance.
To see Spark’s full report on MDP stock, click here.
More about Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company focusing on treatments for rare diseases and complex conditions in North America. Its portfolio includes GRAFAPEX (treosulfan) for Injection, an alkylating agent used as part of a preparative regimen for allogeneic hematopoietic stem cell transplantation in adults and pediatric patients with acute myeloid leukemia or myelodysplastic syndrome in the United States.
Average Trading Volume: 53,473
Technical Sentiment Signal: Buy
Current Market Cap: C$129.8M
See more data about MDP stock on TipRanks’ Stock Analysis page.